icon
icon
icon
icon
Upgrade
icon

Pfizer (PFE.US) and BioNTech (BNTX.US) announced positive results for their flu mRNA vaccine.

AInvestFriday, Aug 16, 2024 7:50 pm ET
1min read

Today, Pfizer (PFE.US) and BioNTech (BNTX.US) announced the latest progress of their second-generation three-valent (tIRV) flu mRNA vaccine in a Phase 2 trial, which showed encouraging data with strong immunogenicity against all virus strains compared to the standard flu vaccine.

It is difficult for global health experts to predict the best-matched virus strains for the next flu season as the virus strains are constantly changing, as they are selected more than six months before the target flu season begins. The flexibility of mRNA technology and its ability to manufacture quickly may enable better virus matching in the coming years, and mRNA technology can also achieve rapid and large-scale vaccine production in the case of a pandemic.

Noes of any safety signals for the vaccine have not been reported so far. Detailed Phase 2 trial data for adults aged 65 and above will be published later.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.